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Effect of Antiretroviral Therapy on Apoptosis
Markers and Morphology in Peripheral Lymph
Nodes of HIV-Infected Individuals
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Abstract
Background: CD4+ T cell depletion and destruction and the
involution of the lymphoid tissue are hallmarks of HIV
infection. Although the underlying mechanisms are still un-
clear, apoptosis appears to play a central role. The objective
of this study was to investigate the effect of antiretroviral
therapy on the lymph node tissue, particularly with respect to
morphology and apoptosis.
Patients and Methods: Between 1997 and 1999, two
inguinal lymph nodes were excised from 31 previously un-
treated individuals who were in an early stage of HIV infec-
tion, the first one prior to treatment and the second after 16
to 20 months of treatment. Paraffin sections were investi-
gated for lymph node architecture, distribution of cellular
and viral markers, apoptosis, and expression of apoptotic key
molecules which indirectly reflect apoptotic processes.
Results: After 16–20 months of antiretroviral therapy, a
significant decrease in highly activated HIV-driven immune
response was observed in the lymph node tissue as a marked
reduction in follicular hyperplasia, a normalization of the
follicular dendritic cell network, a significant increase in the
number of CD4+ T cells, and a significant decrease in the
number of CD8+ T cells. The expression of several pro-
apoptotic (Fas, TRAIL, and active caspase 3) and anti-
apoptotic (Bcl-2 and IL-7Ra) molecules that were reconsti-
tuted in the tissues during therapy resembled their expres-
sion in lymph nodes of HIV-negative individuals. Limitations
of the study are (a) the lack of untreated patients in the late
stages, (b) for ethical reasons, the lack of a control group
with untreated patients, and (c) for methodological reasons,
the restriction of sequential measurements of apotpotic
markers to one-third of the patients.
Conclusion: Antiretroviral therapy initiated in the early
stages in HIV infection may halt the irreversible destruction
of the lymph node tissue and may partially normalize
apoptotic processes
Infection 2008; 36: 120–129
DOI 10.1007/s15010-008-7368-9
Introduction
Potent antiretroviral therapy in HIV-infected patients
leads to a suppression of the HIV load and to a con-
comitant increase in the number of CD4+ T cells [1–3] in
the peripheral blood. However, the regulatory processes
that are important for immune recovery take place in the
lymphoid tissue which acts as a viral reservoir and major
site of HIV replication. HIV preferentially replicates in
CD4+ T lymphocytes, and virus production is 5 to 10
times higher in the lymphoid tissue than that in the
peripheral blood lymphocytes [4–6]. Therefore, we com-
pared lymph nodes that were excised from 31 previously
untreated HIV-infected patients before therapy and after
16–20 months of antiretroviral therapy with respect to
lymph node architecture, the distribution of cellular and
viral markers, and the expression of apoptotic key mole-
cules.
The persistence of HIV replication leads to chronic
immune stimulation [7] and to typical alterations in the
morphology of the lymphoid tissue [8]. Early in HIV-
infection, follicular hyperplasia develops and germinal
centers become infiltrated by cytotoxic CD8+ T cells. This
overactive, massive immune reaction leads to a progres-
sive destruction of follicular dendritic cells and their net-
work within the germinal centers [9, 10]. This and the
parallel depletion of CD4+ T cells lead to hypoplasia and
the involution of the lymphoid tissue, resulting in a
breakdown of the immune system in the advanced stage of
HIV infection [11].
The underlying pathogenic mechanisms that are
responsible for CD4+ T cell depletion in untreated HIV
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infection are not completely understood [12–14]. During
early infection, the cell destruction involves primarily
CCR5+ effector memory T cells and occurs predomi-
nantly in the mucosal tissue, particularly in the intestinal
immune system [15, 16]. Disordered apoptosis and an in-
creased rate of activation-induced cell death (AICD) lead
to destabilization and progressive change of the homeo-
stasis of resting naive and memory T cell populations [14,
17–20]. It is unclear, and even controversial, which of
pro-apoptotic (e.g. Fas, Fas-ligand, TRAIL, and TRAIL-
receptors) and anti-apoptotic (e.g. Bcl-2, c-Flip, and IL-
7Ra) molecules are involved and to what extent.
Patients and Methods
Study Design
Between 1997 and 1999, 31 previously untreated, adult HIV-1-
infected patients, 27 men and 4 women, with a mean age of
35 ± 10 years were enrolled in this study. Twenty-four patients
were treated with dual combination therapy that included one
nucleoside reverse transcriptase and one protease inhibitor; seven
patients were treated with a triple combination therapy that in-
cluded one nucleoside reverse transcriptase and two protease
inhibitors.
In all 31 patients, one inguinal lymph node was excised
before the onset of therapy and a second node was excised after
16–20 months of therapy. The lymphoid tissue was fixed in for-
malin, embedded in paraffin and grouped according to the
classification of the European Study Group [21]. At the time of
each excision, peripheral blood was also drawn from the patient
to obtain CD4+ and CD8+ T cell counts. The viral load was
determined in plasma (detection limit = 500 copies/ml) by using
the HIV Amplicor Monitor (Roche Switzerland).
The project was approved by the Ethical Committee of the
University Hospital Lausanne. The written informed consent was
obtained from all participants.
Immunostaining of the Lymph Node Tissue
Paraffin sections of the lymph node tissue were immunohisto-
chemically stained for the following antigens: CD4 (Novocastra,
clone 1F6, dilution 1:20), CD8 (Dako Cytomation Copenhagen
Denmark, clone, C8/144B), CD21 (Cell Marque, clone 2G9), p24
(Dako, clone Kal-1,1:4), Bcl-2 (Dako, clone 124), IL-7Ra (Santa
Cruz Biotechnologies, 1:100), c-Flip [22] (1:400), Fas (Novocas-
tra, clone GM30; 1:20), FasL [22] (1:80), TRAIL (Santa Cruz
Biotechnologies, K-18, 1:75), and active caspase 3 (R&D;
1:1,500). The sections were stained according to the manufac-
turers’ instructions; horse radish peroxidase (HRP)-conjugate
(Envision + system, Dako) and AEC substrate (Dako) were
used except for the CD4 stains, in which the ABC-Elite-Complex
(Vector laboratories Inc, Burlingame, CA, USA) and DAB
substrate (Dako) were used.
Apoptotic cells were detected by using the TUNEL technique
with the In Situ Cell Detection Kit (Roche Diagnostics) according
to the manufacturer’s protocol. Control slides, which were incu-
bated only with the conjugates, did not show any staining.
The sections were counterstained with Mayer’s hematoxylin
(Fluka, Buchs, Switzerland) and then mounted with crystal
mount (Biomeda Corp., Foster City, CA, USA).
Lymph nodes that had been excised from five HIV-
negative people were used as controls for the immuno-
histological stains.
Morphometry and Quantification
Morphometric measurements prior to and following therapy
were focused on the secondary follicles because these best reflect
the stage of HIV infection. Photographs were taken by using a
Zeiss Axioplan 2 microscope (Carl Zeiss AG, Switzerland) that
was equipped with a Hamamatsu camera and then analyzed with
the KS300 image analysis software (Carl Zeiss AG, Switzerland).
Regions of interest were segmented and the number of pixels/
segment was converted into mm2 by using defined areas of a
Neubauer counting chamber as the reference.
The total active lymph node area (the cortex – including the
germinal centers, the paracortex, and the medullary cords, but
without medullary sinus and cicatrice tissue) was determined.
The number and size of germinal centers were quantified per
total active lymph node area on sections that were stained for
Bcl-2.
The infiltration of germinal centers by CD8+ T cells was
evaluated on immunohistochemically stained sections by
sequentially measuring the area of up to 10 germinal centers. The
proportion of stained CD8+ cells as determined by their hue,
luminescence, and saturation (HLS) was taken as the grade of
infiltration by CD8+ T lymphocytes.
For p24, the staining was graded only as positive or negative
because the variation between follicles was too high for statistical
analysis.
To quantify apoptosis in lymph node slides, the number
of apoptotic cells within all visible germinal centers using the
TUNEL technique was counted independently by two persons.
To quantify TRAIL, regions of interest were selected and in
two to four of such regions which were converted into mm2, the
number of TRAIL-positive cells was counted independently by
two persons.
For all other cellular (CD4, interfollicular CD8, CD21) and
apoptosis-related antigens (Bcl-2, c-Flip, IL-7Ra, Fas, FasL, active
caspase 3), the gray level intensity was determined by computer-
assisted image analysis using the Openlab program (Improvision,
Coventry, UK) as described by Bachmann et al. [22].
Statistical Analysis
Data were analyzed for differences before and after therapy by
using StatView (StatView, 1998, Abacus Concepts Inc., Berke-
ley, CA, USA). Wilcoxon’s rank sum test was used for analysis of
differences between paired observations for nonparametric dis-
tribution, and paired Student’s t-test was used for differences in
normally distributed variables. Results were considered to be
significant when p < 0.05. Values were expressed as the mean or
median together with the standard deviation (SD) or range.
Results
Peripheral Blood Measurements
The viral load decreased significantly (p < 0.0001) in all 31
patients after a mean time of 18 months of therapy (Table 1)
and was below the detection limit in 28 of 31 cases. The
median CD4+ T cell count in all patients increased signi-
ficantly (Table 1). The overall median CD8+ T cell count
did not change significantly under therapy (Table 1).
Lymph Node Histology
The majority of lymph nodes were larger before therapy
than after therapy (Table 1). Twenty biopsies showed
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Table 1
Alterations in peripheral blood values, lymph node architecture, and apoptosis markers under ART in patients with follicular
hyperplasia (with or without fragmentation; FH) or follicular involution/depletion (F-Inv/Depl).
Before ART 16–20 m of ART p-value
n Baseline values at
first LN excision
n Values at second
LN excision
Peripheral blood
HIV-1 RNA (lg10 copies/ml) 31 4.6 ± 0.45 31 2.8 ± 0.16 < 0.0001
FH 20 4.5 ± 0.49 20 2.7 ± 0.15 < 0.0001
F-Inv/Depl 11 4.6 ± 0.35 11 2.8 ± 0.19 < 0.0001
CD4+ T cells (cells/ll) 31 667 (349–1,213) 31 1,011 (278–2,458) 0.0004
FH 20 625 (349–1,088) 20 986 (278–2,458) 0.0068
F-Inv/Depl 11 742 (403–1,213) 11 1,055 (441–1,900) 0.03
CD8+ T cells (cells/ll) 31 1,162 (452–3,154) 31 1,004 (275–2,826) NS
FH 20 1,171 (463–3,154) 20 1,086 (275–2,826) NS
F-Inv/Depl 11 1,147 (452–1,775) 11 1,240 (349–2,340) NS
Lymph node architecture
Reactive LN area (mm2)/section 31 19.5 ± 7 31 12.1 ± 6 < 0.0001
FH 20 19.4 ± 7 9 13.8 ± 8 0.002
F-Inv/Depl 11 19.7 ± 5 22 11.4 ± 6 0.003
Mean GC size (mm2) 31 1.8 ± 2 31 0.28 ± 0.7 0.0003
FH 20 2.7 ± 2 9 0.7 ± 1.2 < 0.0001
F-Inv/Depl 11 0.26 ± 0.3 22 0.11 ± 0.15 NS
GC number/section 31 12 ± 8 31 6 ± 5 0.0004
FH 20 16 ± 7 9 11 ± 4 0.0004
F-Inv/Depl 11 5 ± 6 22 4 ± 4 NS
CD8+T infiltration of GC (mm2) 26 0.013 ± 0.01 18 0.001 ± 0.003 < 0.0001
FH 19 0.015 ± 0.01 7 0.003 ± 0.005 0.0015
F-Inv/Depl 7 0.006 ± 0.01 11 0.001 ± 0.001 NS
Markers in lymph nodes
CD4 (interfollicular)a 15 1,738 ± 166 15 1,939 ± 143 < 0.0001
FH 9 1,749 ± 189 2 2,101 ± 30 0.008
F-Inv/Depl 6 1,722 ± 139 13 1,914 ± 137 0.03
CD8 (interfollicular)a 16 1,736 ± 88 16 1,516 ± 81 < 0.0001
FH 11 1,726 ± 83 3 1,474 ± 47 0.003
F-Inv/Depl 5 1,759 ± 105 13 1,526 ± 85 0.04
CD21 (follicular)a 12 845 ± 110 12 1,017 ± 100 0.008
FH 10 868 ± 103 6 988 ± 75 0.02
F-Inv/Depl 2 727 ± 61 6 1,047 ± 120 NS
Bcl-2 (mantle zone)a 13 1,218 ± 142 13 1,480 ± 198 < 0.0001
FH 10 1,217 ± 132 6 1,504 ± 242 0.005
F-Inv/Depl 3 1,218 ± 207 7 1,460 ± 169 NS
IL-7Ra (follicular)a 8 875 ± 128 8 947 ± 89 0.01
FH 8 875 ± 128 6 965 ± 91 0.01
F-Inv/Depl 0 2 892 ± 80
TRAILb 21 19 ± 12 21 9 ± 5 0.0015
FH 15 23 ± 12 7 13 ± 7 0.003
F-Inv/Depl 6 10 ± 6 14 8 ± 3 NS
Active caspase 3 (sinusoidal)a 14 2,013 ± 71 14 2,151 ± 74 < 0.0001
FH 10 1,998 ± 78 4 2,159 ± 55 0.005
F-Inv/Depl 4 2,051 ± 27 10 2,148 ± 83 NS
Apoptosis (TUNEL)c 11 12 ± 9 11 9 ± 6 NS
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follicular hyperplasia (8 without and 12 with fragmenta-
tion; representative examples in Figure 1a, c). Ten lymph
nodes showed follicular involution and one follicular
depletion (Table 2). Primary follicles were detected in
only two lymph nodes. The interfollicular T cell area was
hyperplastic in most patients (Figure 1e). The medulla
was rich in plasma cells, and the sinuses showed a prom-
inent immature sinus histiocytosis. None of the lymph
nodes showed histological signs of opportunistic infec-
tions.
After 16–20 months of therapy, the reactive lymph
node area and the mean size of the germinal center de-
creased significantly in all patients (Tables 1, Figure 1b).
The number of patients who developed follicular involu-
tion or depletion increased after therapy (Table 1 and 2).
Of the 20 patients who showed follicular hyperplasia prior
to treatment, nine patients still showed this grade after
therapy; follicular involution was evident in eight; and
follicular depletion in three (Table 2). The lymph nodes
of the 11 patients who had follicular involution/depletion
initially remained at this histological stage during therapy
(Table 2). The number of germinal centers per represen-
tative section decreased significantly after therapy only in
the group of patients with initial follicular hyperplasia
(Table 1). Germinal centers disappeared in the lymph
nodes of five patients. Primary follicles reappeared in
lymph nodes of 17 patients. The interfollicular T cell area
remained cell rich (Figure 1f). The number of CD8+ T
cells that had infiltrated the germinal centers had de-
creased significantly following therapy in the group that
had initially shown follicular hyperplasia (Table 1, Fig-
ures 1d, 2h).
Altogether, after 16–20 months of therapy, the lymph
nodes for the majority of patients showed less follicular
hyperplasia and more involution/depletion, and the nodes
appeared less activated when compared to the corre-
sponding baseline lymph node measurements.
Lymph Node Immunostaining
Not all stains on slides could be evaluated because the
number of germinal centers either decreased or disap-
peared following therapy or because of tissue damage.
HIV p24-, CD4+ T cell-, CD8+ T cell-, and
CD21-Immunostaining
Viral p24 antigen was found only within germinal centers
(Figure 2n, o). Prior to treatment, germinal centers in 21
of the 27 investigated patients were p24 positive, and in
6 patients negative. Following therapy, germinal centers
in four patients became p24 negative, and the lymph
nodes of three patients had lost germinal centers and
Table 1
Continued
Before ART 16–20 m of ART p-value
n Baseline values at
first LN excision
n Values at second
LN excision
FH 9 13 ± 10 6 9 ± 8 NS
F-Inv/Depl 2 8 ± 6 5 9 ± 4 NS
LN: lymph node, GC: germinal center, FH: patients with follicular hyperplasia (with or without fragmentation) before therapy and under ART,
F-Inv/Depl: patients with follicular involution or depletion before therapy and under ART, NS: not significant, m: months, n: number of
patients studied; Peripheral blood: median (range); viral load, lymph node architecture, and markers: mean ± SD (all paired comparisons);
aGray level intensity as evaluated by computer assisted image analysis, bmean TRAIL + cell count/mm2, cmean apoptotic cell count/GC
Figure 1. Lymph node architecture in an HIV-infected patient before
and after antiretroviral therapy (ART). Follicular hyperplasia (FH)
decreased after antiretroviral therapy (a, b). Germinal centers (GC)
were destroyed by infiltrating cells before therapy and then
recovered after antiretroviral therapy (c, d). Note vanishing of
mantle zone (MZ) in C and reappearance in D. The T cell area (TCA)
was cell rich both before and after antiretroviral therapy (e, f).
Hematoxylin–eosin staining, magnifications – a, b: 10·; c–f: 20·.
S. Ehrhard et al. Immune Reconstitution in Lymph Nodes
Infection 36 Æ 2008 Æ No. 2  URBAN & VOGEL 123
Table 2
Histological grading of lymph nodes before and after antiretroviral therapy.
Lymph node grading before antiretroviral therapy n (%) Lymph node grading after 16–20 months
of antiretroviral therapy
n
Follicular hyperplasia 8 (26%) Follicular hyperplasia 6
Follicular involution 2
Follicular hyperplasia with fragmentation 12 (39%) Follicular hyperplasia 1
Follicular hyperplasia with fragmentation 2
Follicular involution 6
Follicular depletion 3
Follicular involution 10 (32%) Follicular involution 9
Follicular depletion 1
Follicular depletion 1 (3%) Follicular depletion 1
n: number of patients
Figure 2. Immunohistochemical
localization of CD4 (brown DAB
reaction product), CD8, CD21, and
p24 (red AEC reaction product) in a
lymph node of a patient before and
after antiretroviral therapy (ART)
and in a lymph node of a HIV-
negative individual. The CD4+ T cell
number interfollicularly increased
after antiretroviral therapy (a, b),
whereas the number of CD8+ T cells
decreased in the T cell area (TCA)
(d, e) and within the germinal
centers (g, h). The follicular
dendritic cell marker CD21 increased
after antiretroviral therapy (j, k).
Note fragmentation of the red
dendritic network by infiltrating
lymphocytes (asterisk). p24
persisted in the germinal centers in
some of the patients (m, n). The
staining in HIV-negative lymph
nodes is shown as controls (c, f, i, l,
o). Hematoxylin counterstain,
magnifications – a–f: 40·; g–p: 20·.
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were p24 negative in the residual lymphoid tissue. In the
remaining 14 patients, p24 persisted in the germinal
centers after a median time of 18 months post-treatment.
The initial six patients with p24-negative germinal
centers remained negative. All lymph nodes from HIV-
negative controls were negative for p24 staining (Fig-
ure 2p).
In the interfollicular area of the lymph nodes, the
numbers of CD4+ T cells increased significantly after
therapy (Figure 2a, b), while interfollicular as well as
germinal center CD8+ T cells decreased significantly in all
treated patients (Table 1, Figure 2d, e, g, h), yielding
staining comparable to lymph nodes of HIV-negative
controls (Figure 2c, f, i).
CD21, a marker for the follicular dendritic network,
was weakly distributed over the germinal centers prior to
therapy (Figure 2k) and condensed significantly after
therapy in 11 of the 12 patients tested (Table 1, Figure 2l),
resembling the staining in the germinal centers of HIV-
negative controls (Figure 2m). A significant CD21 in-
crease was found only in the patients who had follicular
hyperplasia prior to therapy (Table 1).
Figure 3. Expression of apoptosis
and pro-apoptotic and anti-
apoptotic markers (AEC red
reaction product) in the lymph
node of a patient before and after
antiretroviral therapy (ART) and in
the node of an HIV-negative
individual. Bcl-2 positive cells
increased in the mantle zone (MZ)
after antiretroviral therapy (a, b).
IL-7Ra expression increased in
germinal centers after
antiretroviral therapy (d, e). Active
caspase 3 increased in the sinuses
(g, h), and Fas slightly increased in
the germinal centers after
antiretroviral therapy (j, k).
TRAIL was localized in the sinuses
and decreased after antiretroviral
therapy (m, n). Apoptosis
measured by the TUNEL
technique (red stain) was
manifested primarily in the
germinal centers. In higher
magniﬁcations (not shown here),
apoptosis was mainly identiﬁed as
tingible bodies in starry–sky
macrophages and as single,
scattered apoptotic bodies (p, q).
The staining of the same markers is
shown in HIV-negative lymph
nodes (c, f, i, l, o, r). Hematoxylin
counterstain, magniﬁcations: a–c,
k–o: 20·; d–i: 40·; p–r: 10·.
S. Ehrhard et al. Immune Reconstitution in Lymph Nodes
Infection 36 Æ 2008 Æ No. 2  URBAN & VOGEL 125
Apoptosis in Germinal Centers
Apoptosis as measured in paired lymph nodes obtained
from 11 patients was preferentially detected in germinal
centers; only a few apoptotic cells were found interfolli-
cularly (Figure 3q, r), very similar as in the lymph nodes
of uninfected individuals (Figure 3s). Apoptosis was
manifested primarily as tingible bodies in starry sky
macrophages as well as in single, scattered apoptotic
bodies. Following therapy, a significant decrease in
apoptosis was detected in lymph nodes on eight patients
(p = 0.02), but a slight increase was found in three pa-
tients; this yields no statistical significance when all 11
patients were considered together as a group (Table 1).
Immunostaining of Pro-apoptotic and
Anti-apoptotic Molecules
The anti-apoptotic Bcl-2 molecules expressed mainly in B
lymphocytes of the mantle zone had significantly
increased in all 13 patients who could be evaluated after
therapy (Table 1, Figure 3a, b). Only a few Bcl-2 positive
cells were found in the germinal centers and in the in-
terfollicular T cell area before and after therapy. IL-7Ra,
which was expressed mainly in centrocytes and centro-
blasts of the germinal centers, increased significantly after
therapy (Table 1, Figure 3d, e). Active caspase 3 showed
a significant increase in the sinuses of the lymph nodes
(Table 1, Figure 3k, i) but not in the germinal centers
after therapy (not shown). After therapy, staining for
these three apoptotic molecules (Figure 3b, e, h) were
very similar in intensity and distribution to the staining in
HIV-negative control sections (Figure 3c, f, i).
TRAIL staining was detectable in polynucleated
granulocytes, in mononuclear histiocytes, and in scattered
granular cells that resembled basophils. TRAIL-positive
cells were found primarily within vessels and sinuses,
some within the interfollicular stroma, and only a few in
the germinal centers (Figure 3n, o). The number of
TRAIL-positive cells decreased significantly after therapy
in the patients who were tested (Table 1). Only a few
TRAIL-positive cells were found in the lymph nodes of
HIV-negative individuals (Figure 3p).
The increase in Bcl-2, IL-7Ra, and active caspase 3
and the decrease in TRAIL were significant only in the
group of patients that originally showed follicular hyper-
plasia in their lymphoid tissue.
The staining of the anti-apoptotic cFlip and the pro-
apoptotic Fas (Figure 3k, l) and FasL antigens did not
change markedly following therapy and looked similar to
staining in the lymph node tissue from HIV-negative
individuals (Figure 3m, data not shown).
Discussion
The patients of this study were in the early stages of HIV
infection as indicated by the still high CD4+ T cell counts
in the blood (> 500 cells/ll) and the absence of advanced
follicular destruction and atrophy in the lymph nodes. We
show that in these patients, antiretroviral therapy, which
lowers the viral load and thus reduces the excessively high
antigenic stimulation, markedly diminishes the HIV-dri-
ven, highly activated immune response in lymph nodes.
This is manifested by:
• A marked reduction of follicular hyperplasia: In early
HIV infection, follicular hyperplasia is considered to
be a physiological reaction of humoral antiviral
immunity. The reduction of germinal centers in size
and number after therapy fits well with the observed
reduction of the viral antigen p24.
• A reconstitution of the follicular dendritic cell net-
work: The disruption and fragmentation of dendritic
network and involution of germinal centers are hall-
marks of HIV pathology brought about by the abnor-
mal infiltration with CD8+ T cells and their destructive
activity on these cells known to carry the virus. The
reconstitution of the network corresponds very well
with the observed CD8+ T cell reduction and prom-
inent although not always complete loss of antigen on
these target cells.
• A reconstitution of Bcl-2-positive mantle zone lym-
phocytes: The B cell system is affected by HIV
infection also at the level of bone marrow derived
mantle cells, probably due to the lack of helper factors
from CD4 T helper cells. The observed sign of
recovery of this committed stem cell compartment
indicates a regeneration of the B cell system.
• The appearance of primary follicles: Their presence
indicates a revival of primary B immune responses
which are obviously exhausted by an exaggerated
secondary immune response with germinal center
formation before therapy.
• A significant increase in the CD4+ T cell number in
the interfollicular area in association with a strong
reduction of the CD8+ T cell number in the same area
and in the germinal centers. This shift within the two T
cell populations in all likelihood reflects the central
effect of therapy by reducing viral effects on CD4 T
cells and reducing the generation of cytotoxic CD8
cells directed against the former.
• A normalization of the apoptotic markers as evidenced
by a distribution of the expression of pro-apoptotic
and anti-apoptotic molecules that is similar to that of
the uninfected lymph node tissue.
Prior to therapy, the majority of lymph nodes showed
reactive follicular hyperplasia, often with giant germinal
centers and/or pathologic fragmentation of germinal
centers. After 16 to 20 months of therapy, the lymph
nodes that were excised from these same patients showed
a marked reduction in lymph node and germinal center
size and also a significant decrease in the number of
germinal centers. Primary germinal centers, which were
virtually absent prior to therapy, reappeared in the lymph
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nodes of a majority of the patients. In addition, the
structure of the germinal centers normalized in most
patients – some becoming very small, presumably as a
consequence of the reduction of germinal center cells and
of CD8+ T cells that had infiltrated the germinal centers
and that may have had induced the damage. Because the
interfollicular area in these patients remained cell rich,
this decrease was likely due to a reduction in immune
stimulation rather than to progression to a virus-induced
degenerative stage.
HIV persists in the germinal centers throughout the entire
course of HIV infection [23], and some viruses remain
trapped on the surface of follicular dendritic cell. The
antiviral response directly or indirectly (via bystander
killing) leads to the destruction of the follicular dendritic
cells network as the HIV infection progresses [11]. Zhang
et al. [11] and Kuster et al. [24] reported that with present
therapeutic options, complete abolition of viral replica-
tion within the lymphoid tissue was not achieved, and
Fischer et al. [25] showed residual HIV-1 RNA in tonsil
biopsy specimen obtained from patients receiving anti-
retroviral therapy indicating attenuated viral transcription
in HIV infected cells that lack virion production. In our
study, from the initial 21 patients with p24 positive lymph
nodes, only 7 became p24 negative during therapy, while
the plasma viral load decreased significantly in all 31 pa-
tients.
In agreement with results of other studies [11, 26, 27],
the follicular dendritic cell network recovered after ther-
apy, as shown by a significant increase in CD21. In most of
our patients, however, the follicular dendritic cell network
was not completely disrupted prior to therapy, presum-
ably because the patients were still in an early stage of
HIV infection.
CD8+ T cells are the key effectors of the antiviral
defense, thereby mediating the destruction taking place in
the lymph nodes. Blackburn et al. [28] reported that the
extent of anti-HIV activity by CD8+ T cells in the lym-
phoid tissue correlated with the viral burden. We found a
high number of CD8+ T cells in the interfollicular area
and within the germinal centers before treatment, fol-
lowed by a significant decrease after treatment. Consistent
with other studies [27, 29, 30], the CD4+ T cell numbers in
the lymph nodes increased significantly after therapy.
The lowering of the highly activated immune re-
sponse is also reflected by the normalization of some
important pro- and anti-apoptotic markers. The expres-
sion of Bcl-2, IL-7Ra, TRAIL, and active caspase 3 was
different in the lymph nodes that were excised 16–
20 months after treatment and markedly resembled
expression in non-infected individuals. Moreover, in 8 of
the 11 patients who were tested for these markers,
apoptosis decreased after therapy, which indicated that
apoptotic processes may have normalized with therapy.
The decrease in apoptosis in germinal centers combined
with the fact that active caspase 3 was only increased in
the sinuses but not in germinal centers indicates a caspase-
independent cell death pathway in germinal centers. In-
deed, it has been shown that productive HIV infection can
lead to caspase independent cell death [31].
Only a few other investigators have looked for
apoptotic markers and apoptosis in lymph nodes; most
have looked for them in peripheral blood lymphocytes.
Interestingly, cellular distribution of several molecules
seems to differ in lymph node lymphocytes and periph-
eral blood lymphocytes, although this may be in part due
to technical reasons. The peripheral blood markers were
determined by FACS analysis, while the markers in the
lymph nodes were identified by immunohistochemistry.
For example, although Bcl-2 was found to be expressed
in peripheral T-lymphocytes and strongly correlated with
spontaneous T cell apoptosis [32–35], in lymph nodes,
Bcl-2 was detected primarily in the B (mantle zone of
the germinal centers) and not in the T cell area. Simi-
larly, IL-7Ra was found to be expressed on peripheral T
and B cells, and peripheral CD4+ T cell depletion cor-
related well with the down-regulation of IL-7Ra [36, 37].
In lymph nodes, IL-7Ra which increased after therapy
was detectable only in the germinal centers and not in
the T cell area. The absence of IL-7Ra expression in the
T cell area resembles those peripheral T cells in which a
strong association of decreased IL-7Ra expression with
low Bcl-2 expression has been found [36, 37]. In lymph
nodes, a significant down-regulation of TRAIL was
found after therapy due primarily to the reduction of
cells of the phagocytic type, whereas TRAIL was not
identifiable in B or T lymphocytes. In peripheral blood,
TRAIL has been discussed as a major death-ligand in
HIV infection [38]. Thus, TRAIL, but not FasL-depen-
dent AICD, was found in peripheral CD4+ T cells that
were isolated from HIV-infected individuals [39, 40].
Whether the CD4+ T cell recovery in lymph nodes after
therapy is the consequence of the marked decrease of
TRAIL-positive cells is unknown. When the apoptotic
and histological markers were correlated, significant
differences before and after therapy were found only in
the group of patients with follicular hyperplasia. The
failure to demonstrate significant differences before and
after therapy in the follicular involution/depletion group
may be due to the less numbers of patients tested in this
study.
This study has some limitations: (a) Untreated
patients who were in the early stages of HIV infection
were selected for this study, but we have no comparison
group of untreated patients in an advanced stage of HIV
infection. (b) For ethical reasons, there is no matched
control group of untreated HIV patients in early stages of
HIV infection. (c) For technical reasons, apoptosis could
only be followed sequentially in the lymph nodes of one-
third of the patients in the study, and the apoptotic
markers that were measured reflect indirect apoptotic
processes.
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However, because histological assessments were done
in parallel, we believe that the results of the study are
valid. The strength of the study is the considerable num-
ber of patients from whom sequential lymph node tissue
samples have been investigated, together with the analysis
of a comprehensive number of immunological, virological,
and histological parameters.
In conclusion, two processes might be involved in the
current therapeutic setting of these patients: (a) a pro-
gression of degenerative changes in the germinal centers
as part of the virus-induced pathology in spite of therapy,
and (b) the physiological reduction of a hyperimmune
response as a result of therapy. Conventional histology
indicates that viral damage prevails after involution has
been established. The arrest of viral pathology and nor-
malization of follicular hyperplasia appears to prevail in
the stage of follicular hyperplasia. However, even in cases
of persistent involution, there are signs of restoration,
such as repopulation of the mantle zone, restoration of the
dendritic net, normalization of apoptotic markers, and the
appearance of primary follicles.
Our data are consistent with observations made in
patients with primary HIV infection who were treated
with antiretroviral therapy and cyclosporin A [41]. Rapid
shutdown of T cell activation by cyclosporin A in the early
phase of HIV infection proved to be beneficial for both
immunological and virological measures by preventing
ongoing infection of new target cells in the lymphoid tis-
sue [2, 42]. Recent reports have shown that immune
reconstitution in the intestinal lymphoid tissues did not
take place after antiretroviral therapy in acute and early
stage HIV infection [43, 44]. Because the intestinal lym-
phoid system, as opposed to the inguinal lymph nodes, is
constantly exposed to a huge number of different anti-
gens, the continuously overactivated immune response
may be more prone to the damaging effect of HIV
infection. Therefore, HIV pathogenesis may be different
in the intestinal lymphoid tissue and inguinal lymph node
tissue.
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